Skip to main content
. Author manuscript; available in PMC: 2023 Mar 30.
Published in final edited form as: Nat Med. 2022 Jun 20;28(7):1432–1438. doi: 10.1038/s41591-022-01861-9

Extended Data Fig. 8: Changes in biomarkers of liver fibrosis after 12 weeks of treatment with licogliflozin.

Extended Data Fig. 8:

Data presented in subfigures (a–c) as geometric mean ratio to baseline, and in subfigure d, as mean change from baseline. a, PRO-C3; b, APRI; c, FIB4; d, NAFLD fibrosis score. Baseline is defined as the last available measurement prior to the first dose. P values based on two-sided ANCOVA test. N for placebo, licogliflozin 30 mg, and 150 mg are 21, 43, and 37 (APRI, FIB4, NAFLD fibrosis score) 20, 42, and 34 (Pro-C3). Error bars represent s.e.